Rifampicin seems to act as both an inducer and an inhibitor of the metabolism of repaglinide
- 19 March 2004
- journal article
- clinical trial
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 60 (2) , 109-114
- https://doi.org/10.1007/s00228-004-0746-z
Abstract
To investigate if rifampicin is both an inducer and an inhibitor of repaglinide metabolism, it was determined whether the timing of rifampicin co-administration influences the pharmacokinetics of repaglinide.Keywords
This publication has 26 references indexed in Scilit:
- Influence of drugs interacting with CYP3A4 on the pharmacokinetics, pharmacodynamics, and safety of the prandial glucose regulator repaglinide.2003
- Gemfibrozil Inhibits CYP2C8-Mediated Cerivastatin Metabolism in Human Liver MicrosomesDrug Metabolism and Disposition, 2002
- Expression and Induction of CYP2C P450 Enzymes in Primary Cultures of Human HepatocytesThe Journal of Pharmacology and Experimental Therapeutics, 2002
- Shed human enterocytes as a tool for the study of expression and function of intestinal drug‐metabolizing enzymes and transportersClinical Pharmacology & Therapeutics, 2002
- Gemfibrozil is a potent inhibitor of human cytochrome P450 2C9.2001
- Rifampin decreases the plasma concentrations and effects of repaglinideClinical Pharmacology & Therapeutics, 2000
- Review of prandial glucose regulation with repaglinide: a solution to the problem of hypoglycaemia in the treatment of Type 2 diabetes?International Journal of Obesity, 2000
- Morning spot and 24-hour urinary 6 beta-hydroxycortisol to cortisol ratios: intraindividual variability and correlation under basal conditions and conditions of CYP 3A4 induction.1999
- Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes.Journal of Clinical Investigation, 1992
- The increase in urinary excretion of 6 beta‐hydroxycortisol as a marker of human hepatic cytochrome P450IIIA induction.British Journal of Clinical Pharmacology, 1989